Read by QxMD icon Read

Vox Sanguinis

C Politis, J C Wiersum, C Richardson, P Robillard, J Jorgensen, P Renaudier, J-C Faber, E M Wood
BACKGROUND AND OBJECTIVES: The International Haemovigilance Network's ISTARE is an online database for surveillance of all adverse reactions (ARs) and adverse events (AEs) associated with donation of blood and transfusion of blood components, irrespective of severity or the harm caused. ISTARE aims to unify the collection and sharing of information with a view to harmonizing best practices for haemovigilance systems around the world. MATERIALS AND METHODS: Adverse reactionss and adverse events are recorded by blood component, type of reaction, severity and imputability to transfusion, using internationally agreed standard definitions...
September 22, 2016: Vox Sanguinis
C Négrier, C Rothschild, J-Y Borg, T Lambert, S Claeyssens, L Sanhes, N Stieltjes, A Bertrand, M-H André, P Sié, Y Gruel, Z Tellier
BACKGROUND AND OBJECTIVES: A new fibrinogen concentrate Clottafact(®) was developed according to European guidelines on plasma-derived products. A post-authorization safety study was set up in 2009 as part of the risk management plan. This was a non-interventional, prospective, non-comparative, multicenter study of the use of fibrinogen concentrate for congenital afibrinogenemia in real-life medical practice in France. MATERIALS AND METHODS: The analysis was descriptive and performed on 3 subgroups: prophylaxis vs...
September 1, 2016: Vox Sanguinis
C R Seed, P Kiely, V C Hoad, A J Keller
BACKGROUND AND OBJECTIVES: We previously published a model to estimate the residual risk (RR) for occult hepatitis B infection (OBI) in the absence of universal anti-HBc testing. To incorporate new information on the epidemiology of OBI, we describe model refinements and estimate a more accurate HBV RR due to OBI in Australia. MATERIALS AND METHODS: In our original model, the OBI risk, p(OBI), was defined by the rate of 'non-detection' by the HBV DNA screening test in use, p(NAT non-detection), and the average infectivity of blood components from OBI donors, p(transmission)...
August 26, 2016: Vox Sanguinis
T Burnouf, J M Dye, J Ambe, A Abayomi
No abstract text is available yet for this article.
August 26, 2016: Vox Sanguinis
C Caram-Deelder, A L Kreuger, J Jacobse, J G van der Bom, R A Middelburg
BACKGROUND: The storage time of platelet products negatively affects bacterial safety and platelet function. However, low maximum storage time increases outdating of valuable products. Thus, to quantify the effect of platelet storage time on platelet measurements after platelet transfusion, a systematic review and meta-analyses were performed. METHODS: Reports and meeting abstracts of randomized trials and observational studies, performed in humans, reporting platelet measurements after transfusion of platelet products of different storage times, were selected until February 2016...
August 26, 2016: Vox Sanguinis
M Goldman, K Magnussen, J Gorlin, M Lozano, J Speedy, A Keller, J Pink, J N S Leung, C C Y Chu, C-K Lee, J Faed, J Chay, H H Tan, D Teo, R Djoudi, G Woimant, A-M Fillet, J Castrén, G Miflin, G C Vandewalle, V Compernolle, J M Cardenas, L Infanti, A Holbro, A Buser, K van den Hurk, V J Yahalom, V Gendelman, E Shinar, A F Eder, W R Steele, E M O'Neill, H Kamel, R Vassallo, G Delage, A Lebrun, P Robillard, M Germain, M Gandhi, K A West, H G Klein
No abstract text is available yet for this article.
August 26, 2016: Vox Sanguinis
J D Roback
BACKGROUND & OBJECTIVES: Red blood cells (RBCs) may be stored up to 42 days before transfusion, per US and EU standards. Although there is ample evidence that RBCs undergo deleterious changes during storage, studies assessing outcomes relative to storage time report conflicting findings. This study investigated RBC storage duration perspectives and practices among blood banking and transfusion professionals. MATERIALS & METHODS: A survey was administered at the American Association of Blood Banking annual meeting in October 2014 (N = 69)...
August 23, 2016: Vox Sanguinis
H-S Lee, K-M Choi, E J Won, M-T Thi Phan, S Y Lee, D-J Shin, S Chun, G Park, S-K Kim, K-B Lee, H-J Lee, D Cho
A novel A subgroup allele (c.538C>T p.Arg180Cys) showing weak A phenotype was found in a 30-year-old Korean woman with ABO discrepancy. Using 3D structural analysis, protein stability prediction and flow cytometric analysis of ABO antigen expression on HeLa cells transfected with plasmids containing the p.Arg180Cys mutant, we found that the Arg180 residue in the loop region of the A glycosyltransferases (GTA) structure plays significant role in stabilizing its closed conformation, which is required for substrate binding and catalysis study...
August 18, 2016: Vox Sanguinis
S Oikawa, M Minegishi, K Endo, W Kawashima, K Suzuki, H Shimizu
This study evaluated the in vitro properties of platelets (PLTs) washed with BRS-A additive solution in the Haemonetics ACP215 automated processing system. Two washing modes, 'manually/automatically adding ACD-A to BRS before/during the washing process', represented the control and test groups, respectively. Outcomes were compared over 7 days of storage (n = 7, for both). PLT recovery following washing processing (26-27 min) was 86·2 ± 1·7% and 86·0 ± 2·2% and plasma protein removal was 98·8 ± 0·3% and 99·0 ± 0·2% in the control and test groups, respectively (not significant)...
August 10, 2016: Vox Sanguinis
J L Bueno, M Ynigo, C de Miguel, R M Gonzalo-Daganzo, A Richart, C Vilches, C Regidor, J A García-Marco, E Flores-Ballester, J R Cabrera
Recent research suggests that growth differentiation factor 11 (GDF11) could reverse age-related diseases and that its blood concentration decreases with age. This poses plasma from young donors as a therapeutic GDF11 source to treat age-related diseases. In addition, the tissue source of circulating GDF11 remains unknown. We analysed GDF11 levels in paired samples of serum, plasma and platelet lysate (PL) from 23 volunteers. Plasma and PL were collected by plateletpheresis. Here, we show that GDF11 is highly concentrated in platelets and that the circulating levels reported in previous studies could be biased as a result of serum sample manipulation...
August 10, 2016: Vox Sanguinis
H B Feys, H Pottel, J Coene, G Vandewalle, P Vandekerckhove, V Compernolle
Platelet apheresis sometimes causes persistent aggregates (PA). This study (n = 211) shows that changing the apheresis settings to reach fixed product volumes instead of yields does not influence PA incidence, even though PA products on average contain more platelets than controls. Furthermore, logistic regression was used to model if PA can be predicted on the basis of certain predonation parameters. PA donation history was the only parameter retained, proving a strong determinant of predictability [AUC = 0...
August 10, 2016: Vox Sanguinis
J Banerjee, T S Leung, N Aladangady
BACKGROUND AND OBJECTIVE: The objective of the study was to investigate the splanchnic blood flow velocity and oximetry response to blood transfusion in preterm infants according to postnatal age. MATERIALS AND METHODS: Preterm infants receiving blood transfusion were recruited to three groups: 1-7 (group 1; n = 20), 8-28 (group 2; n = 21) and ≥29 days of life (group 3; n = 18). Superior mesenteric artery (SMA) peak systolic (PSV) and diastolic velocities were measured 30-60 min pre- and post-transfusion using Doppler ultrasound scan...
August 10, 2016: Vox Sanguinis
M T Bruun, K Pendry, J Georgsen, P Manzini, M Lorenzi, A Wikman, D Borg-Aquilina, E van Pampus, M van Kraaij, D Fischer, P Meybohm, K Zacharowski, C Geisen, E Seifried, G M Liumbruno, G Folléa, J Grant-Casey, P Babra, M F Murphy
BACKGROUND AND OBJECTIVES: Patient Blood Management (PBM) in Europe is a working group of the European Blood Alliance with the initial objective to identify the starting position of the participating hospitals regarding PBM for benchmarking purposes, and to derive good practices in PBM from the experience and expertise in the participating teams with the further aim of implementing and strengthening these practices in the participating hospitals. METHODS: We conducted two surveys in seven university hospitals in Europe: Survey on top indications for red blood cell use regarding usage of red blood cells during 1 week and Survey on PBM organization and activities...
August 10, 2016: Vox Sanguinis
(no author information available yet)
No abstract text is available yet for this article.
October 2016: Vox Sanguinis
(no author information available yet)
No abstract text is available yet for this article.
October 2016: Vox Sanguinis
V M A Voorn, A van der Hout, C So-Osman, T P M Vliet Vlieland, R G H H Nelissen, M E van den Akker-van Marle, A Dahan, P J Marang-van de Mheen, L van Bodegom-Vos
BACKGROUND AND OBJECTIVES: To determine the value of erythropoietin in reducing allogeneic transfusions, it is important to assess the effects, safety and costs for individual indications. Previous studies neither compared the effects of erythropoietin between total hip and total knee arthroplasty, nor evaluated the safety or costs. We performed a meta-analysis to assess the effects of erythropoietin in total hip and knee arthroplasty separately. Safety and costs were evaluated as secondary outcomes...
October 2016: Vox Sanguinis
A S de Vos, R W Lieshout-Krikke, E Slot, E A Cator, M P Janssen
BACKGROUND AND OBJECTIVES: Individuals may donate blood in order to determine their infection status after exposure to an increased infection risk. Such test-seeking behaviour decreases transfusion safety. Instances of test seeking are difficult to substantiate as donors are unlikely to admit to such behaviour. However, manifestation in a population of repeat donors may be determined using statistical inference. MATERIALS AND METHODS: Test-seeking donors would be highly motivated to donate following infection risk, influencing the timing of their donation...
October 2016: Vox Sanguinis
H M Faddy, J J Fryk, D Watterson, P R Young, N Modhiran, D A Muller, S D Keil, R P Goodrich, D C Marks
BACKGROUND: Dengue viruses (DENV 1-4) are emerging across the world, and these viruses pose a risk to transfusion safety. Pathogen inactivation may be an alternative approach for managing the risk of DENV transfusion transmission. This study aimed to investigate the ability of riboflavin and UV light to inactivate DENV 1-4 in platelet concentrates. MATERIALS AND METHODS: DENV 1-4 were spiked into buffy coat-derived platelet concentrates in additive solution (SSP+) before being treated with riboflavin and UV light...
October 2016: Vox Sanguinis
T Minagi, H Okamoto, M Ikegawa, S Ideno, K Takahashi, K Sakai, K Hagiwara, M Yunoki, A Wakisaka
BACKGROUND AND OBJECTIVES: Human hepatitis E virus (HEV) is prevalent worldwide. Iatrogenic HEV has recently been identified based on the reports of transfusion-transmitted cases. The detection rate of HEV-RNA and seroprevalence of HEV-IgG/IgM have been regionally evaluated in Japan, and donor plasma collected in Hokkaido is currently screened by nucleic acid amplification testing. However, the detection rate of HEV-RNA in blood donors in Japan outside of Hokkaido has not been reported...
October 2016: Vox Sanguinis
C K Okerberg, L A Williams, M L Kilgore, C H Kim, M B Marques, J Schwartz, H P Pham
BACKGROUND: Fibrinogen repletion in patients with acquired bleeding disorders can be accomplished by transfusing cryoprecipitate AHF (cryo) or fibrinogen concentrate (FC); thus, we undertook an economic evaluation from the transfusion service perspective regarding the use of cryo vs. FC in patients with acquired bleeding. METHODS: We created a model comparing the cost of cryo vs. FC from the transfusion service perspective. A patient with acquired bleeding requiring fibrinogen replacement could receive either 15-20 cryo units or 3-4 g FC, consistent with the guidelines from the European Task Force for Advanced Bleeding Care in Trauma...
October 2016: Vox Sanguinis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"